These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35956989)

  • 1. Targeting Glutaminase by Natural Compounds: Structure-Based Virtual Screening and Molecular Dynamics Simulation Approach to Suppress Cancer Progression.
    Tabrez S; Zughaibi TA; Hoque M; Suhail M; Khan MI; Khan AU
    Molecules; 2022 Aug; 27(15):. PubMed ID: 35956989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of rat renal phosphate-dependent glutaminase with 6-diazo-5-oxo-L-norleucine. Evidence for interaction at the glutamine binding site.
    Shapiro RA; Clark VM; Curthoys NP
    J Biol Chem; 1979 Apr; 254(8):2835-8. PubMed ID: 429321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and drug-likeness of anti-cancer traditional Chinese medicine: molecular docking and molecular dynamics simulation study.
    Khan K; Albalawi K; Abbas MN; Burki S; Musad Saleh EA; Al Mouslem A; Alsaiari AA; A Zaki ME; Khan AU; Alotaibi G; Jalal K
    J Biomol Struct Dyn; 2024 Apr; 42(7):3295-3306. PubMed ID: 37279114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
    Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
    Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase.
    Zimmermann SC; Duvall B; Tsukamoto T
    J Med Chem; 2019 Jan; 62(1):46-59. PubMed ID: 29969024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Cathepsin L in Cancer Management: Leveraging Machine Learning, Structure-Based Virtual Screening, and Molecular Dynamics Studies.
    Almalki AA; Shafie A; Hazazi A; Banjer HJ; Bakhuraysah MM; Almaghrabi SA; Alsaiari AA; Alsaeedi FA; Ashour AA; Alharthi A; Alharthi NS; Anjum F
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based virtual screening discovers novel kidney-type glutaminase inhibitors.
    Lin LC; Chang HY; Lin TE; Lin JR; Hsia SM; Hsu KC; Huang TC
    Biomed Pharmacother; 2022 Oct; 154():113585. PubMed ID: 36029536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant production and characterization of L-glutaminase (glsA) as a promiscuity therapeutic enzyme.
    Simay S; Akbarzadeh-Khiavi M; Pourseif MM; Barar J; Safary A; Omidi Y
    Appl Microbiol Biotechnol; 2022 Sep; 106(17):5511-5524. PubMed ID: 35876873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based virtual screening of influenza virus RNA polymerase inhibitors from natural compounds: Molecular dynamics simulation and MM-GBSA calculation.
    Jin Z; Wang Y; Yu XF; Tan QQ; Liang SS; Li T; Zhang H; Shaw PC; Wang J; Hu C
    Comput Biol Chem; 2020 Apr; 85():107241. PubMed ID: 32120300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for the active site inhibition mechanism of human kidney-type glutaminase (KGA).
    Thangavelu K; Chong QY; Low BC; Sivaraman J
    Sci Rep; 2014 Jan; 4():3827. PubMed ID: 24451979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutaminase inhibitors: a patent review.
    Wu C; Chen L; Jin S; Li H
    Expert Opin Ther Pat; 2018 Nov; 28(11):823-835. PubMed ID: 30273516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of compelling inhibitors of human norovirus 3CL protease to combat gastroenteritis: A structure-based virtual screening and molecular dynamics study.
    He S; Nahhas AF; Habib AH; Alshehri MA; Alshamrani S; Asiri SA; Alnamshan MM; Helmi N; Al-Dhuayan I; Almulhim J; Alharbi AM; Su D; Kumari A; Rahaman A
    Front Chem; 2022; 10():1034911. PubMed ID: 36247661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic characterization of ebselen, chelerythrine and apomorphine as glutaminase inhibitors.
    Thomas AG; Rojas C; Tanega C; Shen M; Simeonov A; Boxer MB; Auld DS; Ferraris DV; Tsukamoto T; Slusher BS
    Biochem Biophys Res Commun; 2013 Aug; 438(2):243-8. PubMed ID: 23850693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target-based virtual screening, computational multiscoring docking and molecular dynamics simulation of small molecules as promising drug candidate affecting kinesin-like protein KIFC1.
    Khan MKA; Ahmad S; Rabbani G; Shahab U; Khan MS
    Cell Biochem Funct; 2022 Jul; 40(5):451-472. PubMed ID: 35758564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circ-CREBBP promotes cell tumorigenesis and glutamine catabolism in glioma by regulating miR-375/glutaminase axis.
    Zhang L; Ye L; Xu Z; Jin Y; Song D
    Brain Res; 2022 Jan; 1775():147730. PubMed ID: 34813772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions.
    Xu X; Meng Y; Li L; Xu P; Wang J; Li Z; Bian J
    J Med Chem; 2019 Feb; 62(3):1096-1115. PubMed ID: 30148361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scaffold-based Screening and Molecular Dynamics Simulation Study to Identify Two Structurally Related Phenolic Compounds as Potent MMP1 Inhibitors.
    Patra S; Saravanan P; Das B; Subramanian V; Patra S
    Comb Chem High Throughput Screen; 2020; 23(8):757-774. PubMed ID: 32342802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure and activation mechanism of the human liver-type glutaminase GLS2.
    Ferreira IM; Quesñay JEN; Bastos AC; Rodrigues CT; Vollmar M; Krojer T; Strain-Damerell C; Burgess-Brown NA; von Delft F; Yue WW; Dias SM; Ambrosio AL
    Biochimie; 2021 Jun; 185():96-104. PubMed ID: 33746066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.
    Lampa M; Arlt H; He T; Ospina B; Reeves J; Zhang B; Murtie J; Deng G; Barberis C; Hoffmann D; Cheng H; Pollard J; Winter C; Richon V; Garcia-Escheverria C; Adrian F; Wiederschain D; Srinivasan L
    PLoS One; 2017; 12(9):e0185092. PubMed ID: 28950000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LincRNA-p21 suppresses glutamine catabolism and bladder cancer cell growth through inhibiting glutaminase expression.
    Zhou Q; Zhan H; Lin F; Liu Y; Yang K; Gao Q; Ding M; Liu Y; Huang W; Cai Z
    Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30902882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.